Deutetrabenazine - Teva Pharmaceutical

Drug Profile

Deutetrabenazine - Teva Pharmaceutical

Alternative Names: AUSTEDO; d6-tetrabenazine; Deuterium-substituted tetrabenazine; Dutetrabenazine; SD-809; SD-809 ER; SD-809 Extended Release; TEV-50717

Latest Information Update: 07 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Auspex Pharmaceuticals
  • Developer Nuvelution Pharma; Teva Pharmaceutical Industries
  • Class Antipsychotics; Neuroprotectants; Organic deuterium compounds; Quinolizines; Small molecules
  • Mechanism of Action Dopamine receptor antagonists; Dopamine release inhibitors; Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease; Gilles de la Tourette's syndrome
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chorea; Drug-induced dyskinesia
  • Phase III Gilles de la Tourette's syndrome

Most Recent Events

  • 22 Jun 2018 Phase-III clinical trials in Gilles de la Tourette's syndrome (In adolescents, In children) in USA (PO) (NCT03571256)
  • 06 Jun 2018 Teva Branded Pharmaceutical Products initiates enrolment in a phase III trial for Tourette Syndrome (In children, In adolescents) in Hungary (EudraCT2017-002976-24)
  • 05 Jun 2018 Phase-III clinical trials in Gilles de la Tourette's syndrome (In children, In adolescents) in Hungary (PO) (EudraCT2016-000630-22)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top